Sinil Pharmaceutical Co. Ltd (012790) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.017x

Based on the latest financial reports, Sinil Pharmaceutical Co. Ltd (012790) has a cash flow conversion efficiency ratio of 0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.62 Billion ≈ $1.78 Million USD) by net assets (₩151.71 Billion ≈ $102.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sinil Pharmaceutical Co. Ltd stock valuation for the company's overall valuation and market capitalisation.

Sinil Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Sinil Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Sinil Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sinil Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency. Explore Sinil Pharmaceutical Co. Ltd (012790) cash flow quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
HLV LIMITED NSE:HLVLTD	0.007x
TSI Co. Ltd. KQ:277880	0.219x
Sun Peak Metals Corp V:PEAK	-0.049x
Brand Engagement Network Inc NASDAQ:BNAI	-0.512x
Altamira Gold Corp V:ALTA	-0.007x
CBAK ENERGY TECH. NEW F:B6JA	0.218x
Yura Tech. Co. Ltd KQ:048430	0.021x
MINDs Lab Inc. KQ:377480	-0.082x

Annual Cash Flow Conversion Efficiency for Sinil Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Sinil Pharmaceutical Co. Ltd from 2014 to 2024. View Sinil Pharmaceutical Co. Ltd (012790) share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩146.51 Billion ≈ $99.28 Million	₩22.69 Billion ≈ $15.38 Million	0.155x	+37.85%
2023-12-31	₩134.90 Billion ≈ $91.42 Million	₩15.15 Billion ≈ $10.27 Million	0.112x	+1.18%
2022-12-31	₩123.28 Billion ≈ $83.54 Million	₩13.69 Billion ≈ $9.28 Million	0.111x	+12.59%
2021-12-31	₩113.20 Billion ≈ $76.71 Million	₩11.16 Billion ≈ $7.57 Million	0.099x	-4.18%
2020-12-31	₩107.48 Billion ≈ $72.84 Million	₩11.06 Billion ≈ $7.50 Million	0.103x	-15.33%
2019-12-31	₩101.24 Billion ≈ $68.61 Million	₩12.31 Billion ≈ $8.34 Million	0.122x	+25.83%
2018-12-31	₩95.18 Billion ≈ $64.51 Million	₩9.19 Billion ≈ $6.23 Million	0.097x	+1.27%
2017-12-31	₩90.93 Billion ≈ $61.62 Million	₩8.67 Billion ≈ $5.88 Million	0.095x	-31.23%
2016-12-31	₩87.19 Billion ≈ $59.09 Million	₩12.09 Billion ≈ $8.20 Million	0.139x	+13.38%
2015-12-31	₩78.17 Billion ≈ $52.98 Million	₩9.56 Billion ≈ $6.48 Million	0.122x	-7.08%
2014-12-31	₩70.85 Billion ≈ $48.01 Million	₩9.33 Billion ≈ $6.32 Million	0.132x	--

About Sinil Pharmaceutical Co. Ltd

KQ:012790 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$47.47 Million

₩70.05 Billion KRW

Market Cap Rank

#22181 Global

#1383 in Korea

Share Price

₩6060.00

Change (1 day)

+1.00%

52-Week Range

₩4900.00 - ₩6480.00

All Time High

₩50717.45